182 related articles for article (PubMed ID: 34143801)
1. Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa.
Ogawa C; Tsuchiya K; Tomosugi N; Maeda K
PLoS One; 2021; 16(6):e0252439. PubMed ID: 34143801
[TBL] [Abstract][Full Text] [Related]
2. Threshold of Serum Ferritin to Discriminate against Those at Greater Risk of Platelet Increase during Treatment with Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor.
Ogawa C; Tsuchiya K; Tomosugi N; Maeda K
Acta Haematol; 2022; 145(4):412-418. PubMed ID: 35051929
[TBL] [Abstract][Full Text] [Related]
3. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients.
Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A
J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926
[TBL] [Abstract][Full Text] [Related]
4. The target hemoglobin content values of reticulocytes for efficient anemia improvement are achieved by low ferritin levels and moderate transferrin saturation: a retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Shimada K; Kanda F; Maeda K
Hematology; 2020 Dec; 25(1):71-78. PubMed ID: 32009585
[No Abstract] [Full Text] [Related]
5. A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients.
Ogawa C; Tsuchiya K; Tomosugi N; Maeda K
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998272
[TBL] [Abstract][Full Text] [Related]
6. Significance of Content of the Reticulocyte Hemoglobin in the Management of Renal Anemia.
Ogawa C; Tsuchiya K; Nitta K; Maeda K
Blood Purif; 2019; 47 Suppl 2():70-73. PubMed ID: 30943480
[TBL] [Abstract][Full Text] [Related]
7. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
Brătescu LO; Bârsan L; Gârneaţă L; Stanciu A; Lipan M; Stancu SH; Mircescu G
Int Urol Nephrol; 2014 May; 46(5):1005-12. PubMed ID: 24800994
[TBL] [Abstract][Full Text] [Related]
8. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
[TBL] [Abstract][Full Text] [Related]
9. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients.
Ogawa C; Tsuchiya K; Kanda F; Maeda T
Am J Nephrol; 2014; 40(6):561-70. PubMed ID: 25592750
[TBL] [Abstract][Full Text] [Related]
10. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
11. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Li J; Xie QH; You L; Xu NX; Hao CM
Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
[TBL] [Abstract][Full Text] [Related]
12. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
14. Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content.
Mitsuiki K; Harada A; Miyata Y
Clin Exp Nephrol; 2003 Mar; 7(1):52-7. PubMed ID: 14586744
[TBL] [Abstract][Full Text] [Related]
15. Reticulocyte hemoglobin content in hemodialysis patients with acute infection.
Mitsuiki K; Harada A; Miyata Y
Clin Exp Nephrol; 2004 Sep; 8(3):257-62. PubMed ID: 15480904
[TBL] [Abstract][Full Text] [Related]
16. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of iron deficiency testing strategies in hemodialysis patients.
Fishbane S; Shapiro W; Dutka P; Valenzuela OF; Faubert J
Kidney Int; 2001 Dec; 60(6):2406-11. PubMed ID: 11737617
[TBL] [Abstract][Full Text] [Related]
18. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients.
Tsuchiya K; Okano H; Teramura M; Iwamoto Y; Yamashita N; Suda A; Shimada K; Nihei H; Ando M
Clin Nephrol; 2003 Feb; 59(2):115-23. PubMed ID: 12608554
[TBL] [Abstract][Full Text] [Related]
19. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
